News >

Ongoing Advances Transforming Treatment in Myeloma

Caroline Seymour
Published: Monday, Apr 02, 2018

Noa Biran, MD

Noa Biran, MD
Although there is still a gap in physicians’ treatment arsenal for high-risk patients with multiple myeloma, that is not to discount the great strides physicians have made in the landscape, explains Noa Biran, MD.

on Hematologic Malignancies, Biran, of the Myeloma Division at John Theurer Cancer Center, discussed treatment breakthroughs and emerging advances in the field of multiple myeloma.

OncLive: How has the treatment for newly diagnosed multiple myeloma evolved? 

Biran: There are several different areas including transplant-eligible patients, transplant- ineligible patients, and the role of transplant. In the newly diagnosed setting, triplets are better than doublets in both patient populations. They achieve a very rapid and deep response. That usually translates into a longer duration of remission. The SWOG S0777 trial randomized patients who did not go onto transplant to either upfront bortezomib, lenalidomide, and dexamethasone, or lenalidomide and dexamethasone alone. The patients who received the triplet had a much longer PFS and OS. It’s important to keep transplant-ineligible patients on a triplet regimen.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication